KRAS and colorectal cancer: In a study investigating the combination therapy of the FOLFIRI regimen with cetuximab in colorectal cancer, the findings revealed that, compared to monotherapy, the combination therapy demonstrated significant efficacy improvement in patients with KRAS wild‐type tumors, while no similar benefit was observed in the KRAS mutant population.31